大摩:予国药控股(01099)“增持”评级 目标价降至24港元

智通财经
29 Oct 2024

智通财经APP获悉,大摩发布研究报告称,国药控股(01099)公布第三季业绩,由于收入及毛利率下降,对其2024至2030年度盈利预测下调4%至10%。目标价和情境价值下调4至9%。该行将国药目标价由25港元降至24港元,此相当于预测明年市盈率7.9倍,评级“增持”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10